Selective cytotoxicity of diazenecarboxamides towards human leukemic cell lines

Toxicology in Vitro

Volumn 21, Issue 8, 2007, Pages 1453-1459

  Martin Kleiner, I ^a   Bombek, S ^b   Kosmrlj J ^b   Cupic B ^a   Cimbora Zovko T ^a   Jakopec, S ^a   Polanc, S ^b   Osmak, M ^a   Gabrilovac, J ^a  

^a RUDER BO KOVI INSTITUTE   (Croatia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Cytotoxicity; Diazenes; HL 60; JURKAT; K 562; NALM 1; Peripheral blood mononuclear cells

Indexed keywords

AMIDE; CONCANAVALIN A; DIAZENECARBOXAMIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ISOLATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG SELECTIVITY; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; STRUCTURE ANALYSIS;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; HUMANS; IMIDES; LEUKEMIA; MOLECULAR STRUCTURE;

EID: 36049034003     PISSN: 08872333     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tiv.2007.06.005     Document Type: Article

References (21)

1. Boranić M., Krizanac-Bengez Lj., Gabrilovac J., Marotti T., and Breljak D. Enkephalins in hematopoiesis. Biomedicine and Pharmacotherapy 51 (1997) 29-37
2. Collins S.J. The HL-60 promyelocytic leukemia cell line: proliferation, differentiation, and cellular oncogene expression. Blood 70 (1987) 1233-1244
3. Čimbora T., Bombek S., Polanc S., and Osmak M. Methyl 2-(2-Chloroethylaminocarbonyl)diazenecarboxylate SB-166 inhibits the growth of different tumor cell lines, including drug-resistant sublines. Toxicology in Vitro 17 (2003) 159-164
4. Čimbora-Zovko T., Bombek S., Košmrlj J., Kovačič L., Polanc S., Katalinić A., and Osmak M. Development of potential anti-cancer agents: diazenes and derivatives. Drug Development Research 61 (2004) 95-100
5. Cipak L., Paulikova H., Novotny L., Jarosova M., and Rauko P. Potentiation of doxorubicin-induced apoptosis and differentiation by indomethacin in K-562 leukemia cells. Neoplasma 51 (2004) 188-192
6. Fan Y., Schreiber E.M., Giorgianni A., Yalowich J.C., and Day B.W. Myeloperoxidase-catalyzed metabolism of etoposide to its quinone and glutathione adduct forms in HL-60 cells. Chemical Research in Toxicology 19 (2006) 937-943
7. Jakopec S., Dubravčić K., Polanc S., Košmrlj J., and Osmak M. Diazene JK-279 induces apoptosis-like cell death in human cervical carcinoma cells. Toxicology in Vitro 20 (2006) 217-226
8. Jakopec S., Dubravčić K., Brozović A., Polanc S., and Osmak M. Structurally similar diazenes exhibit significantly different biological activity. Cell Biology and Toxicology 22 (2006) 61-71
9. Kanno S., Matsukawa E., Miura A., Shouji A., Asou K., and Ishikawa M. Diethyldithiocarbamate-induced cytotoxicity and apoptosis in leukemia cell lines. Biological Pharmaceutical Bulletin 26 (2003) 964-968
10. Lozzio B.B., and Lozzio C.B. Properties and usefulness of the original K-562 human myelogenous leukemia cell line. Leukemia Research 3 (1979) 363-370
11. Martin-Kleiner I., Gabrilovac J., Kušec R., and Boranić M. Methionine-enkephalin suppresses metabolic activity of a leukemic cell line (NALM-1) and enhances CD10 expression. International Immunopharmacology 3 (2003) 707-711
12. Matsuo Y., and Drexler H.G. Establishment and characterization of human B cell precursor - leukemia cell lines. Leukemia Research 22 (1998) 567-579
13. Moskatelo D., Benjak A., Laketa V., Polanc S., Košmrlj J., and Osmak M. Cytotoxic effects of diazenes on tumor cells in vitro. Chemotherapy 48 (2002) 36-41
14. Moskatelo D., Polanc S., Košmrlj J., Vuković L., and Osmak M. Diazenecarboxamide UP-91, a potential anti-cancer agent, acts by reducing cellular glutathione content. Pharmacology and Toxicology 91 (2002) 258-262
15. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of Immunologic Methods 65 (1983) 55-63
16. Mounetou E., Legault J., Lacroix J., and Gaudreault G.C. Anti-mitotic antitumor agents: Synthesis, structure-activity relationships, and biological characterization of N-Aryl-N′-(2-chloroethyl)ureas as new selective alkylating agents. Journal of Medicinal Chemistry 44 (2001) 694-702
17. Osmak M., Bordukalo T., Jernej B., Košmrlj J., and Polanc S. Diazene JK-279: potential anti-cancer drug. Anti-cancer Drugs 10 (1999) 853-859
18. Osmak M., Bordukalo T., Ristov A.A., Jernej B., Košmrlj J., and Polanc S. Diazenes as modificators of drug-resistance in tumor cells. Neoplasma 47 (2000) 390-395
19. Pieters L., Košmrlj J., Lenaršič R., Kočevar M., and Polanc S. Synthesis and cytotoxicity against human cancer cells of novel diazenecarboxamides. ARKIVOC (Part V) (2001) 42-50
20. Polanc S. New synthetic applications and biological activity of diazenes. Journal of Heterocyclic Chemistry 42 (2005) 401-412
21. Ramos A.M., Fernandez C., Amran D., Sancho P., de Blas E., and Aller P. Pharmacologic inhibitors of PI3K/Akt potentiate the apoptotic action of the anti-leukemic drug arsenic trioxide via glutathione depletion and increased peroxide accumulation in myeloid leukemia cells. Blood 105 (2005) 4013-4020